ArticleFrontiers in oncology2020
IGF2BP2 Promotes Liver Cancer Growth Through an m6A-FEN1-Dependent Mechanism.
Article in Frontiers in oncology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 90 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
90 citing papers in PubMed, 160 citations in OpenAlex.
- Integrative analysis of the roles and prognostic value of RNA-binding proteins in papillary renal cell carcinoma.Discover oncology · 2026Article
- The mMolecular biomedicine · 2026Article
- mFrontiers in cell and developmental biology · 2026Review
- m6A reader IGF2BP2 mediates paclitaxel resistance in esophageal squamous cell carcinoma via FOXM1 mRNA stabilization.Oncology reports · 2025Article
- mActa pharmaceutica Sinica. B · 2025Review
- Hypoxia-mediated mJournal of translational medicine · 2025Review
- Targeting m6A methylation for early diagnosis and precision medicine in hepatocellular carcinoma.Cancer cell international · 2025Review
- Flap endonuclease-1 promotes pancreatic cancer progressionWorld journal of gastrointestinal oncology · 2025Article
- N6-methyladenosine readerWorld journal of gastroenterology · 2025Article
- Article
- Article
- IGF2BP2: an mCellular & molecular biology letters · 2025Review
- METTL3, an Independent Adverse Prognostic Factor for AML, Promotes the Development of AML by Modulating the PGC-1α-MAPK Pathway and PGC-1α-Antioxidant System Axis.Cancer medicine · 2025Article
- IMPlications of IMP2 in RNA Biology and Disease.International journal of molecular sciences · 2025Review
- Multifaceted roles of insulin‑like growth factor 2 mRNA binding protein 2 in human cancer (Review).Molecular medicine reports · 2025Review
- IGF2BP2 contributes to thyroid cancer progression by enhancing the stability of m6A-modified CTSH mRNA.PloS one · 2025Article
- The mRecent patents on anti-cancer drug discovery · 2025Article
- The mFrontiers in oncology · 2025Article
- IGF2BP2 promotes lung adenocarcinoma progression by regulating LOX1 and tumor-associated neutrophils.Immunologic research · 2024Article
- High WTAP expression level as a promising biomarker for poor prognosis in colorectal cancer: a pilot study.European journal of histochemistry : EJH · 2024Article
30 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Hepatocellular carcinoma (HCC) is one of the most common malignant tumors in China. N6-methyladenosine (m6A) plays an important role in posttranscriptional gene regulation. METTL3 and IGF2BP2 are key genes in the m6A signal pathway and have recently been shown to play important roles in cancer development and progression. In our work, higher METTL3 and IGF2BP2 expression were found in HCC tissues and were associated with a poor prognosis. In addition, IGF2BP2 overexpression promoted HCC proliferation
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.